Suppr超能文献

室间质量评价/能力验证在全面癌症基因组检测中对基因变异检测的重要性。

Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing.

作者信息

Matsushita Kazuyuki, Ishige Takayuki, Watanabe Kousuke, Akahane Toshiaki, Tanimoto Akihide, Yoshimoto Michiko, Yamakuchi Munekazu, Hashiguchi Teruto, Okugawa Yoshinaga, Ikejiri Makoto, Yamaguchi Toshikazu, Yamasaki Tadashi, Takeda Mayu, Hibi Masaaki, Akiyama Naoki, Shimizu Kaho, Hashimoto Naonori, Sato Hiroko, Tanaka Yoshinori, Amari Fumie

机构信息

Department of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana Chuo-ku, Chiba, 260-8670, Japan.

Division of Clinical Genetics and Proteomics/Center for Cancer Genomes/Center for Ultrasound, Chiba University Hospital, 1-8-1 Inohana Chuo-ku, Chiba, 260-8670, Japan.

出版信息

Sci Rep. 2025 Jan 7;15(1):1036. doi: 10.1038/s41598-024-84714-4.

Abstract

Comprehensive genomic profiling (CGP) is increasingly used as a clinical laboratory test and being applied to cancer treatment; however, standardization and external quality assessments (EQA) have not been fully developed. This study performed cost-effective EQA and proficiency tests (PT) for CGP testing among multiple institutions those belong to the EQA working group of Japan Association for Clinical Laboratory Science (JACLS). This study revealed that preanalytical processes, such as derived nucleic acids (NA) extraction from formalin fixed paraffine embedded (FFPE) samples, are critical. First, EQA with extracted DNA from cell lines showed a detection rate of 100% (9 out of 9) in KRAS (c.38G > A; p.G13D), PIK3CA (p.H1047R), and B-Raf proto-oncogene, serine/threonine kinase (BRAF) (c.1799 T > A; p.V600E) in cases of > 10% variant allele frequency (VAF). However, BRAF (c.1799 T > A; p.V600E) detection decreased to 67% (6 out of 9) for a VAF of 4.9%. Second, when DNA was extracted from FFPE samples, pathogenic variants and variants with companion diagnostic indications were detected in all 10 participating laboratories. Each variant had < 20% VAFs on average (8.1-19.1%) and wide variability among laboratories was observed (relative standard deviation, 13-60%). Nonetheless, BRAF (c.1798_1799delinsAA; p.V600K) of 8.1% VAF, EGFR (c.2235_2249del; p.E746_A750del) of 9.7% VAF, and EGFR (c.2254_2277del; p.S752_I759del) of 9.8% VAF were detected with 70% (7/10), 70% (7/10), and 60% (6/10) frequency, respectively. Therefore, 10% VAF in pre-analytic processing for DNA extraction from FFPE was critical for variant detection in CGP analysis. Further, incorrect results were reported in case independent variant calling of BRAF; c.1798_1799delinsAA (p.V600K) was mistakenly interpreted as c.1798G > A, and c.1799 T > A was on the other strand. In conclusion, the EQA/PT among 10 institutes with common samples revealed the importance of VAF in pre-analysis and helped us understand the significance of the pipeline and common pitfalls usually ignored by the internal quality control in a single institute.

摘要

综合基因组分析(CGP)越来越多地被用作一种临床实验室检测手段并应用于癌症治疗;然而,标准化和外部质量评估(EQA)尚未得到充分发展。本研究针对隶属于日本临床检验科学协会(JACLS)EQA工作组的多个机构开展了CGP检测的成本效益型EQA和能力验证试验(PT)。该研究表明,分析前过程,如从福尔马林固定石蜡包埋(FFPE)样本中提取核酸(NA),至关重要。首先,对从细胞系中提取的DNA进行的EQA显示,在变异等位基因频率(VAF)>10%的情况下,KRAS(c.38G>A;p.G13D)、PIK3CA(p.H1047R)和B-Raf原癌基因丝氨酸/苏氨酸激酶(BRAF)(c.1799T>A;p.V600E)的检测率为100%(9例中的9例)。然而,对于4.9%的VAF,BRAF(c.1799T>A;p.V600E)的检测率降至67%(9例中的6例)。其次,当从FFPE样本中提取DNA时,所有10个参与实验室均检测到了致病变异和具有伴随诊断指征的变异。每个变异的平均VAF<20%(8.1-19.1%),且各实验室之间存在较大差异(相对标准偏差为13-60%)。尽管如此,VAF为8.1%的BRAF(c.1798_1799delinsAA;p.V600K)、VAF为9.7%的表皮生长因子受体(EGFR)(c.2235_2249del;p.E746_A750del)和VAF为9.8%的EGFR(c.2254_2277del;p.S752_I759del)的检测频率分别为70%(7/10)、70%(7/10)和60%(6/10)。因此,在从FFPE中提取DNA的分析前处理中,10%的VAF对于CGP分析中的变异检测至关重要。此外,在BRAF的独立变异检测中报告了错误结果;c.1798_1799delinsAA(p.V600K)被错误地解释为c.1798G>A,而c.1799T>A位于另一条链上。总之,10个机构使用共同样本进行的EQA/PT揭示了分析前VAF的重要性,并帮助我们了解了流程的重要性以及单个机构内部质量控制通常忽略的常见陷阱。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ced8/11704004/3138f8a8e796/41598_2024_84714_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验